以根治性目的行消融放疗治疗寡转移肉瘤（OSCAR）：一项代表意大利放疗与临床肿瘤学会（AIRO）开展的多中心研究。
Oligometastatic sarcoma treated with Curative intent Ablative Radiotherapy (OSCAR): A multicenter study on behalf of AIRO (Italian association of Radiotherapy and clinical Oncology).
作者信息
Franceschini D, Greto D, Dicuonzo S, Navarria F, Federico M, La Vecchia M, Sangalli C, Allajbej A, Di Cristina L, Mazzola R, Pontoriero A, Montesi G, Navarria P, Baldaccini D, Clerici E, Lo Faro L, Franzese C, Di Biase S, Pergolizzi S, Alongi F, Bignardi M, Fazio I, Mascarin M, Jereczek-Fossa B A, Livi L, Scorsetti M
机构信息
Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
出版信息
Radiother Oncol. 2024 Feb;191:110078. doi: 10.1016/j.radonc.2023.110078. Epub 2023 Dec 30.
BACKGROUND AND PURPOSE
Stereotactic Ablative Radiotherapy (SABR) is emerging as a valid alternative to surgery in the oligometastatic setting in soft tissue sarcomas (STS), although robust data are lacking. The aim of this study is to evaluate toxicity and efficacy of SABR in oligometastatic STS.
MATERIALS AND METHODS
This is a retrospective multicenter study including adult patients affected by stage IV STS, treated with SABR for a maximum of 5 cranial or extracranial metastases in up to 3 different organs. SABR was delivered with ablative purposes. Study endpoints were overall survival (OS), local control (LC), distant progression free survival (DPFS), time to polymetastatic progression (TTPP), time to new systemic therapy (TTNS) and toxicity.
RESULTS
From 10 Italian RT centers, 138 patients (202 metastases) treated between 2010 and 2022 were enrolled in the study. Treatment was generally well tolerated, no acute or late toxicity ≥ G3 was recorded. Median follow up was 42.5 months. Median OS was 39.7 months. Actuarial OS at 1 and 2 years was 91.5 % and 72.7 %. Actuarial LC at 1 and 2 years was 94.8 % and 88.0 %. Median DPFS was 9.7 months. Actuarial DPFS at 1 and 2 years was 40.8 % and 19.4 %.
CONCLUSION
SABR is a safe and effective approach for the treatment of oligometastatic sarcoma. One out of 5 patients is free of progression at 2-years.
背景与目的
立体定向消融放疗（SABR）在软组织肉瘤（STS）寡转移的治疗中逐渐成为一种有效的手术替代方案，尽管相关有力数据尚缺。本研究旨在评估SABR治疗寡转移STS的毒性和疗效。
材料与方法
这是一项回顾性多中心研究，纳入成年IV期STS患者，接受SABR治疗，最多治疗3个不同器官中的5个颅部或颅外转移灶。SABR以消融目的进行。研究终点为总生存期（OS）、局部控制（LC）、远处无进展生存期（DPFS）、发生多转移进展的时间（TTPP）、开始新的全身治疗的时间（TTNS）以及毒性。
结果
来自10个意大利放疗中心，2010年至2022年期间治疗的138例患者（202个转移灶）纳入研究。治疗总体耐受性良好，未记录到≥3级的急性或晚期毒性反应。中位随访时间为42.5个月。中位OS为39.7个月。1年和2年的精算OS分别为91.5%和72.7%。1年和2年的精算LC分别为94.8%和88.0%。中位DPFS为9.7个月。1年和2年的精算DPFS分别为40.8%和19.4%。
结论
SABR是治疗寡转移肉瘤的一种安全有效的方法。五分之一的患者在2年时无疾病进展。
Zotero 插件